Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms.

Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M.

Ann Surg Oncol. 2008 Sep;15(9):2465-71. doi: 10.1245/s10434-008-9992-0. Epub 2008 Jun 13.

PMID:
18551347
2.

Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours.

Yao J, Gan G, Farlow D, Laurence JM, Hollands M, Richardson A, Pleass HC, Lam VW.

ANZ J Surg. 2012 Mar;82(3):140-4. doi: 10.1111/j.1445-2197.2011.05972.x. Epub 2012 Jan 17.

PMID:
22510123
3.

Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?

Casneuf V, Delrue L, Kelles A, Van Damme N, Van Huysse J, Berrevoet F, De Vos M, Duyck P, Peeters M.

Acta Gastroenterol Belg. 2007 Oct-Dec;70(4):331-8.

PMID:
18330088
4.

Combination of FDG PET/CT and contrast-enhanced MSCT in detecting lymph node metastasis of esophageal cancer.

Tan R, Yao SZ, Huang ZQ, Li J, Li X, Tan HH, Liu QW.

Asian Pac J Cancer Prev. 2014;15(18):7719-24.

5.

A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.

Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.

Ann Surg. 2009 Dec;250(6):957-63. doi: 10.1097/SLA.0b013e3181b2fafa.

PMID:
19687736
6.

Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma.

Einersen P, Epelboym I, Winner MD, Leung D, Chabot JA, Allendorf JD.

J Gastrointest Surg. 2014 Aug;18(8):1441-4. doi: 10.1007/s11605-014-2529-x. Epub 2014 Jun 14.

PMID:
24928186
7.

Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.

Leblanc E, Gauthier H, Querleu D, Ferron G, Zerdoud S, Morice P, Uzan C, Lumbroso S, Lecuru F, Bats AS, Ghazzar N, Bannier M, Houvenaeghel G, Brenot-Rossi I, Narducci F.

Ann Surg Oncol. 2011 Aug;18(8):2302-9. doi: 10.1245/s10434-011-1583-9. Epub 2011 Feb 23.

PMID:
21347790
8.

Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?

Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL.

J Thorac Oncol. 2014 Aug;9(8):1202-6. doi: 10.1097/JTO.0000000000000222.

9.
10.

Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.

Goodfellow H, Viney Z, Hughes P, Rankin S, Rottenberg G, Hughes S, Evison F, Dasgupta P, O'Brien T, Khan MS.

BJU Int. 2014 Sep;114(3):389-95. doi: 10.1111/bju.12608. Epub 2014 Apr 16.

11.

Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.

Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, Urso GK, Dachille MA, Townsend DW.

Clin Nucl Med. 2000 Nov;25(11):882-7.

PMID:
11079584
12.

Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.

Lemke AJ, Niehues SM, Hosten N, Amthauer H, Boehmig M, Stroszczynski C, Rohlfing T, Rosewicz S, Felix R.

J Nucl Med. 2004 Aug;45(8):1279-86.

13.

PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer.

Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A.

Clin Nucl Med. 2015 Nov;40(11):e501-5. doi: 10.1097/RLU.0000000000000837.

14.

Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness.

Heinrich S, Goerres GW, Schäfer M, Sagmeister M, Bauerfeind P, Pestalozzi BC, Hany TF, von Schulthess GK, Clavien PA.

Ann Surg. 2005 Aug;242(2):235-43.

15.

Accuracy of multi-detector computed tomography, fluorodeoxyglucose positron emission tomography-CT, and CA 19-9 levels in detecting recurrent pancreatic adenocarcinoma.

Hamidian Jahromi A, Sangster G, Zibari G, Martin B, Chu Q, Takalkar A, Shi R, Shokouh-Amiri H.

JOP. 2013 Jul 11;14(4):466-8. doi: 10.6092/1590-8577/1529.

16.

Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.

Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, Teramoto N, Yamamoto K, Inoue T, Iguchi H.

Pancreas. 2013 Jan;42(1):11-9. doi: 10.1097/MPA.0b013e3182550d77.

18.

The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer.

Kim MJ, Lee KH, Lee KT, Lee JK, Ku BH, Oh CR, Heo JS, Choi SH, Choi DW.

Pancreas. 2012 Aug;41(6):897-903. doi: 10.1097/MPA.0b013e318252f4f5.

PMID:
22699202
19.

[Benefit of PET/CT in the preoperative staging in pancreatic carcinomas].

Kysucan J, Lovecek M, Klos D, Tozzi I, Koranda P, Buriánková E, Neoral C, Havlík R.

Rozhl Chir. 2010 Aug;89(7):433-40. Czech.

PMID:
20925260
20.

Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.

Billé A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, Mancini M, Ardissone F.

Eur J Cardiothorac Surg. 2009 Sep;36(3):440-5. doi: 10.1016/j.ejcts.2009.04.003. Epub 2009 May 22. Review.

PMID:
19464906

Supplemental Content

Support Center